Login
$TRVI
$13.29 -$0.36 (2.64%) Live

$TRVI SEC Filings

Filed On Filing
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting

27 Oct 2026 SCHEDULE 13G/A
17 Sep 2026 Form 4: Heffernan Michael Thomas, Director

Received 39,473 shares by exercise or conversion ($126K) · Sold 39,473 shares ($596K)

15 Sep 2026 144
06 Aug 2026 S-8
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

06 Aug 2026 SCHEDULE 13G/A
04 Jun 2026 Form 4: Mathers Edward T, Director

Granted 35,000 Nonstatutory Stock Option (right to buy)

04 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

(Pursuant to Section 242 of theGeneral Corporation Law of the State of Delaware)

04 Jun 2026 Form 4: Colangelo Dominick, Director

Granted 35,000 Nonstatutory Stock Option (right to buy)

04 Jun 2026 Form 4: Meeker David P, Director

Granted 35,000 Nonstatutory Stock Option (right to buy)

04 Jun 2026 Form 4: Vanlent Anne, Director

Granted 35,000 Nonstatutory Stock Option (right to buy)

04 Jun 2026 Form 4: Heffernan Michael Thomas, Director

Granted 35,000 Nonstatutory Stock Option (right to buy)

07 May 2026 SCHEDULE 13D/A
06 May 2026 SCHEDULE 13G/A
05 May 2026 10-Q
05 May 2026 8-K: Results of Operations and Financial Condition

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement

21 Apr 2026 Proxy statement: annual meeting on June 3, 2026

CEO pay $3.9M, up 52% · say-on-pay vote

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support